文献速递造血干细胞移植与细胞治疗血栓与止血

PTCy联合西罗莫司与MMF预防外周血单倍体移植后GVHD的2期试验

A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation.
PubMed 文献 · Blood Adv · 2021-01-01

该2期试验评估在外周血单倍体造血干细胞移植后,采用移植后环磷酰胺(PTCy)联合西罗莫司和吗替麦考酚酯(MMF)预防移植物抗宿主病(GVHD)的疗效。共32例可评估患者入组,主要终点第100天II-IV级急性GVHD累积发生率为18.8%(95%CI 7.5%-34.0%),达到预设的20%目标。中位随访16.1个月,1年NIH中重度慢性GVHD、非复发死亡、复发、无病生存、无GVHD无复发生存和总生存分别为18.8%、18.8%、22.2%、59.0%、49.6%和71.7%。

要点

  • PTCy联合西罗莫司/MMF方案使外周血单倍体移植后第100天II-IV级aGVHD累积发生率为18.8%。
  • 1年NIH中重度cGVHD累积发生率为18.8%,非复发死亡率为18.8%。
  • 1年总生存率为71.7%,无病生存率为59.0%,无GVHD无复发生存率为49.6%。

核心结论

  • 在外周血单倍体移植后,PTCy联合西罗莫司和MMF预防GVHD可有效预防II-IV级急性GVHD,达到主要终点。
  • 结果支持开展前瞻性研究比较PTCy后西罗莫司与他克莫司分别联合MMF的GVHD预防方案。

研究设计与样本

  • 2期临床试验,评估PTCy后西罗莫司联合MMF预防外周血单倍体移植后GVHD的疗效。
  • 入组32例可评估患者(≥18岁),研究把握度90%以证明第100天II-IV级aGVHD从历史基准40%降至20%。

主要发现

  • 中位随访16.1个月,第100天II-IV级aGVHD累积发生率为18.8%(95%CI 7.5%-34.0%)。
  • 无移植失败事件;1年NIH中重度cGVHD累积发生率为18.8%(95%CI 7.4%-34.0%)。
  • 1年非复发死亡率为18.8%(95%CI 7.4%-34.0%),复发率为22.2%(95%CI 9.6%-38.2%)。
  • 1年无病生存率为59.0%(95%CI 44.1%-79.0%),无GVHD无复发生存率为49.6%(95%CI 34.9%-70.5%),总生存率为71.7%(95%CI 57.7%-89.2%)。

关键数值与推荐

  • 主要终点为第100天II-IV级aGVHD累积发生率,预设目标为从历史基准40%降至20%。
  • 实际第100天II-IV级aGVHD累积发生率为18.8%(95%CI 7.5%-34.0%),达到主要终点。

临床怎么用

  • 外周血单倍体移植后可采用PTCy联合西罗莫司和MMF作为GVHD预防方案,II-IV级aGVHD发生率较低。
  • 该方案下1年中重度cGVHD、非复发死亡和复发率可控,生存结局可接受。

局限性

  • 本研究为单臂2期试验,样本量32例可评估患者,未设随机对照。
  • 历史基准对照可能引入偏倚,需前瞻性随机比较西罗莫司与他克莫司联合MMF的方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of posttransplant cyclophosphamide (PTCy) made performing allogeneic hematopoietic cell transplantation (HCT) from HLA haplotype-incompatible donors possible. In a setting of PTCy and tacrolimus/mycophenolate mofetil (MMF) as a graft-versus-host disease (GVHD) prophylaxis, a peripheral blood (PB) graft source as compared with bone marrow reduces the relapse rate but increases acute GVHD (aGVHD) and chronic GVHD (cGVHD). This phase 2 trial assessed sirolimus and MMF efficacy following PTCy as a GVHD prophylaxis after PB haploidentical HCT (haplo-HCT). With 32 evaluable patients (≥18 years) enrolled, this study had 90% power to demonstrate a reduction in 100-day grade II-IV aGVHD to 20% from the historical benchmark of 40% after haplo-HCT using PTCy/tacrolimus/MMF. At a median follow-up of 16.1 months, the primary end point of the trial was met with a day-100 grade II-IV aGVHD cumulative incidence of 18.8% (95% confidence interval [CI], 7.5% to 34.0%). There were no graft-failure events and the 1-year probability of National Institutes of Health (NIH) moderate/severe cGVHD was 18.8% (95% CI, 7.4% to 34.0%), nonrelapse mortality was 18.8% (95% CI, 7.4% to 34.0%), relapse was 22.2% (95% CI, 9.6% to 38.2%), disease-free survival was 59.0% (95% CI, 44.1% to 79.0%), GVHD-free relapse-free survival was 49.6% (95% CI, 34.9% to 70.5%), and overall survival was 71.7% (95% CI, 57.7% to 89.2%) for the entire cohort. These data demonstrate that GVHD prophylaxis with sirolimus/MMF following PTCy effectively prevents grade II-IV aGVHD after PB haplo-HCT, warranting prospective comparison of sirolimus vs tacrolimus in combination with MMF following PTCy as GVHD prophylaxis after PB HCT. This trial was registered at www.clinicaltrials.gov as #NCT03018223.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bejanyan N, Pidala JA, Wang X, et al. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021. PMID: 33635333. doi:10.1182/bloodadvances.2020003779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。